# NCT04158440 (NCT04158440)

> Phase III Study of Toripalimab Versus Placebo Plus Chemotherapy in Resectable NSCLC

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04158440
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Shanghai Junshi Bioscience Co., Ltd.
- Conditions: Stage II-III Non-small Cell Lung Cancer
- Interventions: 4cycles(Toripalimab IV 240mg + platinum-based doublet chemotherapy)+13 cycles(Toripalimab IV 240mg); Biological: Toripalimab; 4cycles(Placebo + platinum-based doublet chemotherapy)+13 cycles(Placebo )
- Enrollment: 501
- Primary outcome: MPR rate in stage III population evaluated by BIPR
- Primary outcome: EFS in stage III population evaluated by investigators
- Primary outcome: MPR rate in stage II-III population evaluated by BIPR
- Primary outcome: EFS in stage II-III population evaluated by investigators

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 4

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct04158440